TW200720261A - Phenylene derivatives - Google Patents

Phenylene derivatives

Info

Publication number
TW200720261A
TW200720261A TW095131929A TW95131929A TW200720261A TW 200720261 A TW200720261 A TW 200720261A TW 095131929 A TW095131929 A TW 095131929A TW 95131929 A TW95131929 A TW 95131929A TW 200720261 A TW200720261 A TW 200720261A
Authority
TW
Taiwan
Prior art keywords
disorders
dialysis
nephrosis
disease
cataract
Prior art date
Application number
TW095131929A
Other languages
Chinese (zh)
Inventor
Hiroaki Yanagisawa
Kiyoshi Kurokawa
Toshio Miyata
Original Assignee
Sankyo Co
Univ Tokai
Kiyoshi Kurokawa
Toshio Miyata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co, Univ Tokai, Kiyoshi Kurokawa, Toshio Miyata filed Critical Sankyo Co
Publication of TW200720261A publication Critical patent/TW200720261A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel phenylene derivative represented by the general formula (I) and pharmaceutically acceptable salts or esters thereof: [wherein, A represents a group represented by the following general formulas (A1), (A2), (A3) or (A4): and the other symbols have the same meanings as described in the specification], which are useful as therapeutic or prophylactic agents for renal disorders (nephritis, nephrosis, nephrosclerosis, renal failure and the like), diabetes complications (nephrosis, neuropathy, retinopathy, cataract, microangiopathy, dermopathy and the like), cardiovascular diseases (myocardial infarction, cardiac hypertrophy, heart failure, arteriosclerosis, coronary artery diseases, peripheral circulation disorders, cerebrovascular disorders, hypertension, systolic hypertension, restenosis after angioplasty and the like), cerebral metabolism disorders (Alzheimer' s disease, Parkinson's disease and the like), dialysis-related complications such as dialysis-related amyloidosis, peritoneal sclerosis in peritoneal dialysis patients, rheumatoid arthritis, solar elastosis, aging, senile cataract and the like.
TW095131929A 2005-08-31 2006-08-30 Phenylene derivatives TW200720261A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005251826 2005-08-31

Publications (1)

Publication Number Publication Date
TW200720261A true TW200720261A (en) 2007-06-01

Family

ID=37809036

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095131929A TW200720261A (en) 2005-08-31 2006-08-30 Phenylene derivatives

Country Status (3)

Country Link
JP (1) JPWO2007026962A1 (en)
TW (1) TW200720261A (en)
WO (1) WO2007026962A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
JP5288365B2 (en) 2007-07-17 2013-09-11 学校法人東海大学 Examination and treatment of schizophrenia
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EP2454243A2 (en) * 2009-07-15 2012-05-23 Merck Serono SA Tetrazole derivatives
US20130196990A1 (en) 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
ES2899852T3 (en) 2014-12-17 2022-03-15 Pimco 2664 Ltd N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(-4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3748697B2 (en) * 1997-02-05 2006-02-22 三共株式会社 Diabetes complication preventive or therapeutic agent
JP4392131B2 (en) * 2001-03-02 2009-12-24 扶桑薬品工業株式会社 Protein modification product inhibitor and method
WO2002083127A1 (en) * 2001-04-09 2002-10-24 Tokai University Educational System Protein modification-inhibitory compositions
JP2004300153A (en) * 2003-03-20 2004-10-28 Kiyoshi Kurokawa Protein modification product formation inhibitor
KR20060123125A (en) * 2003-09-30 2006-12-01 상꾜 가부시키가이샤 Phenylene derivative having tetrazole ring or thiazolidinedione ring

Also Published As

Publication number Publication date
WO2007026962A1 (en) 2007-03-08
JPWO2007026962A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
TW200720261A (en) Phenylene derivatives
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
NO20081370L (en) Phenyl [1,2,4] -ocadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2008126732A1 (en) Fused bicyclic heteroaryl derivatives
CA2547234A1 (en) The use of quaternary pyridinium salts as vasoprotective agents
YU74102A (en) Malonamic acids and derivatives thereof as thyroid receptor ligands
NZ715983A (en) Vasoprotective and cardioprotective antidiabetic therapy
TWI532731B (en) New pyridazinone and pyridone compounds
ATE469161T1 (en) PYRAZOLE DERIVATIVE, MEDICAL COMPOSITION CONTAINING SAME, MEDICAL USE THEREOF, AND INTERMEDIATE FOR THE PRODUCTION THEREOF
JP7341034B2 (en) Novel therapeutic use of benzylideneguanidine derivatives for the treatment of proteopathy
NO20092293L (en) Sulfonyl-phenyl-2H- [1,2,4] oxodiazole-5-derivatives, process for their preparation and their use as pharmaceutical agents
WO2007085556A3 (en) Use of 4-imidazole derivatives for cns disorders
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005079566A3 (en) Gene disruptions, compositions and methods relating thereto
JP2016524612A (en) Imidazolidinedione compounds and drug compositions
NO20073051L (en) Tetralin and indan derivatives and their use
NO20064951L (en) 1,3,4-oxadiazole-2-ones as PPAR delta modulators and their use
WO2006063811A3 (en) Substituted 1,2,4-triazin-5(2h)-ones
WO2006063813A3 (en) 3-arylalkyl-substituted and 3-heteroarylalkyl-substituted-1,2,4-triazin-5(2h)-ones
CA2310458A1 (en) Piperidine derivatives
NO20073250L (en) Non-aniline derivatives of isothiazole-3- (2H) -one 1,1-dioxides as liver-X receptor modulating compounds.
WO2006094934A8 (en) Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
NZ589019A (en) 3, 4 - substituted piperidine derivatives as renin inhibitors
ATE556708T1 (en) CORROLE FOR NEUROPROTECTION AND NEURO-RESCUE
WO2008035305A3 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia